Innovent Biologics, Inc. is a China-based biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of monoclonal antibodies and other biologic medicines. Its research targets major disease areas including oncology, autoimmune and inflammatory disorders, metabolic diseases, and ophthalmology. The company operates integrated R&D and large-scale GMP manufacturing facilities in Suzhou, enabling end-to-end development from early discovery through commercial supply.
Founded in 2011 and listed on the Hong Kong Stock Exchange, Innovent advances a portfolio that includes both innovative biologics and biosimilars, with several products approved in China and multiple candidates in late-stage clinical development. The company collaborates with global partners and conducts international clinical studies to support broader access and evidence generation for its therapies.
Also known as 信达生物.
None yet. When a new project in the record names Innovent Biologics as owner, partner or investor, it shows here.
Phase 3 G‑HOPE‑001 met dual endpoints in CLDN18.2‑positive advanced G/GEJA—median OS 10.2 vs 6.9 months and PFS 7.1 vs 3.1 months versus physician’s choice.
Takeda acquires rights to IBI363 and IBI343 for global development and commercialization, excluding Greater China, with a $1.2 billion upfront payment to Innovent.
Takeda gains rights to two late-stage cancer drugs and an option for an early-stage program, focusing on global development and commercialization outside Greater China.
